BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26; quiz S27. [PMID: 25091148 DOI: 10.1038/ajg.2014.187] [Cited by in Crossref: 350] [Cited by in F6Publishing: 291] [Article Influence: 43.8] [Reference Citation Analysis]
Number Citing Articles
1 Staudacher HM, Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc. 2016;75:306-318. [PMID: 26908093 DOI: 10.1017/s0029665116000021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
2 Dai L, Zhong LL, Ji G. Irritable bowel syndrome and functional constipation management with integrative medicine: A systematic review. World J Clin Cases 2019; 7(21): 3486-3504 [PMID: 31750331 DOI: 10.12998/wjcc.v7.i21.3486] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:1044-1060. [PMID: 30294792 DOI: 10.1111/apt.15001] [Cited by in Crossref: 150] [Cited by in F6Publishing: 126] [Article Influence: 37.5] [Reference Citation Analysis]
4 Panda H, Andrews CN. Constipation in a 40-year-old woman. CMAJ 2016;188:277-8. [PMID: 26668199 DOI: 10.1503/cmaj.150761] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Piccione M, Facchinello N, Schrenk S, Gasparella M, Pathak S, Ammar RM, Rabini S, Dalla Valle L, Di Liddo R. STW 5 Herbal Preparation Modulates Wnt3a and Claudin 1 Gene Expression in Zebrafish IBS-like Model. Pharmaceuticals (Basel) 2021;14:1234. [PMID: 34959635 DOI: 10.3390/ph14121234] [Reference Citation Analysis]
6 McKenzie YA, Bowyer RK, Leach H, Gulia P, Horobin J, O'Sullivan NA, Pettitt C, Reeves LB, Seamark L, Williams M, Thompson J, Lomer MC; (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association). British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:549-75. [PMID: 27272325 DOI: 10.1111/jhn.12385] [Cited by in Crossref: 115] [Cited by in F6Publishing: 99] [Article Influence: 19.2] [Reference Citation Analysis]
7 DuPont HL. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clin Proc. 2015;90:1116-1124. [PMID: 26162610 DOI: 10.1016/j.mayocp.2015.04.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
8 Coman V, Vodnar DC. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 2020;141:111095. [PMID: 32979504 DOI: 10.1016/j.exger.2020.111095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
9 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG. [Clinical practice guidelines: Irritable bowel syndrome with constipation and functional constipation in adults: Concept, diagnosis, and healthcare continuity. (Part 1 of 2)]. Semergen 2017;43:43-56. [PMID: 27810257 DOI: 10.1016/j.semerg.2016.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD., la semFYC., la SEMERGEN y la SEMG., Sociedad Española de Patología Digestiva (SEPD)., Sociedad Española de Medicina de Familia y Comunitaria (semFYC)., Sociedad Española de Médicos de Atención Primaria (SEMERGEN)., Sociedad Española de Médicos Generales y de Familia (SEMG). [Clinical practice guidelines: Irritable bowel syndrome with constipation and functional constipation in adults: Concept, diagnosis, and healthcare continuity. (Part 1 of 2)]. Aten Primaria 2017;49:42-55. [PMID: 28027792 DOI: 10.1016/j.aprim.2016.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Chen JH, Yu Y, Yang Z, Yu WZ, Chen WL, Yu H, Kim MJ, Huang M, Tan S, Luo H, Chen J, Chen JD, Huizinga JD. Intraluminal pressure patterns in the human colon assessed by high-resolution manometry. Sci Rep. 2017;7:41436. [PMID: 28216670 DOI: 10.1038/srep41436] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
12 Basnayake C. Treatment of irritable bowel syndrome. Aust Prescr 2018;41:145-9. [PMID: 30410210 DOI: 10.18773/austprescr.2018.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. J Clin Med 2017;6:E101. [PMID: 29077050 DOI: 10.3390/jcm6110101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
14 Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 23.5] [Reference Citation Analysis]
15 Saito YA, Almazar AE, Tilkes KE, Choung RS, Van Norstrand MD, Schleck CD, Zinsmeister AR, Talley NJ. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019;49:389-97. [PMID: 30663077 DOI: 10.1111/apt.15077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
16 Igbinedion SO, Ansari J, Vasikaran A, Gavins FN, Jordan P, Boktor M, Alexander JS. Non-celiac gluten sensitivity: All wheat attack is not celiac. World J Gastroenterol 2017; 23(40): 7201-7210 [PMID: 29142467 DOI: 10.3748/wjg.v23.i40.7201] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
17 McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. J Acad Nutr Diet 2017;117:251-64. [PMID: 27863994 DOI: 10.1016/j.jand.2016.09.021] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 24.8] [Reference Citation Analysis]
18 Yang F, Zhong B, Kumar A, Chow S, Ouyang A. Exchanging Social Support Online: A Longitudinal Social Network Analysis of Irritable Bowel Syndrome Patients’ Interactions on a Health Forum. Journalism & Mass Communication Quarterly 2018;95:1033-57. [DOI: 10.1177/1077699017729815] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
19 Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM; ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113:1-18. [PMID: 29950604 DOI: 10.1038/s41395-018-0084-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 113] [Article Influence: 46.7] [Reference Citation Analysis]
20 Bodmer NA, Thakrar KH. Evaluating the Patient with Left Lower Quadrant Abdominal Pain. Radiol Clin North Am 2015;53:1171-88. [PMID: 26526432 DOI: 10.1016/j.rcl.2015.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Patel N, Lacy B. Does Yoga Help Patients With Irritable Bowel Syndrome? Clin Gastroenterol Hepatol 2016;14:1732-4. [PMID: 27552854 DOI: 10.1016/j.cgh.2016.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019;114:21-39. [PMID: 30177784 DOI: 10.1038/s41395-018-0222-5] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 30.0] [Reference Citation Analysis]
23 Garnock-jones KP. Eluxadoline: First Global Approval. Drugs 2015;75:1305-10. [DOI: 10.1007/s40265-015-0436-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
24 Gracie DJ, Ford AC. IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol. 2015;8:101-109. [PMID: 25733921 DOI: 10.2147/ceg.s58153] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.1] [Reference Citation Analysis]
25 Klingelhoefer L, Reichmann H, Korczyn AD, Reichmann H, Chaudhuri KR. Parkinson’s Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options – A Practise Guide. JPD 2015;5:647-58. [DOI: 10.3233/jpd-150574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Kawamura Y, Yamamoto S, Funaki Y, Ohashi W, Yamamoto K, Ozeki T, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, Ebi M, Ogasawara N, Sasaki M, Kasugai K. Internet survey on the actual situation of constipation in the Japanese population under 70 years old: focus on functional constipation and constipation-predominant irritable bowel syndrome. J Gastroenterol 2020;55:27-38. [PMID: 31428873 DOI: 10.1007/s00535-019-01611-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Li P, Shen M, Lou GC, Chen YW, Wu WQ. Meta-analysis of mesalazine for irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2015; 23(30): 4911-4918 [DOI: 10.11569/wcjd.v23.i30.4911] [Reference Citation Analysis]
28 Safari D, DeMarco EC, Scanlon L, Grossberg GT. Over-The-Counter Remedies in Older Adults: Patterns of Use, Potential Pitfalls, and Proposed Solutions. Clin Geriatr Med 2022;38:99-118. [PMID: 34794706 DOI: 10.1016/j.cger.2021.07.005] [Reference Citation Analysis]
29 Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2017;112:365-374. [PMID: 27922029 DOI: 10.1038/ajg.2016.542] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
30 Wu WK, Chen CC, Panyod S, Chen RA, Wu MS, Sheen LY, Chang SC. Optimization of fecal sample processing for microbiome study - The journey from bathroom to bench. J Formos Med Assoc 2019;118:545-55. [PMID: 29490879 DOI: 10.1016/j.jfma.2018.02.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
31 Ford AC. Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease? Clin Gastroenterol Hepatol 2015;13:1944-5. [PMID: 26240007 DOI: 10.1016/j.cgh.2015.07.039] [Reference Citation Analysis]
32 Mokhtare M, Karimi S, Bahardoust M, Sotoudeheian M, Ghazi A, Babaei-Ghazani A. How adding the abdominal massage to polyethylene glycol can improve symptom and quality of life in patients with functional constipation in comparison with each one of the treatment modalities alone: A randomized clinical trial. Complement Ther Med 2020;52:102495. [PMID: 32951744 DOI: 10.1016/j.ctim.2020.102495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pettit J, Glickman-Simon R. Osteopathic Manipulative Therapy for Preterm Infants, Acupuncture for Menopausal Symptoms, Mindfulness-Based Stress Reduction for Chronic Low Back Pain, Chocolate for Ischemic Heart Disease, Berberine for Irritable Bowel Syndrome. Explore (NY) 2016;12:388-92. [PMID: 27473312 DOI: 10.1016/j.explore.2016.06.015] [Reference Citation Analysis]
34 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
35 Pace LA, Crowe SE. Complex Relationships Between Food, Diet, and the Microbiome. Gastroenterol Clin North Am 2016;45:253-65. [PMID: 27261897 DOI: 10.1016/j.gtc.2016.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
36 Arokiadoss A, Weber HC. Targeted pharmacotherapy of irritable bowel syndrome. Curr Opin Endocrinol Diabetes Obes 2021;28:214-21. [PMID: 33481423 DOI: 10.1097/MED.0000000000000618] [Reference Citation Analysis]
37 McRorie JW Jr, Fahey GC Jr, Gibb RD, Chey WD. Laxative effects of wheat bran and psyllium: Resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation. J Am Assoc Nurse Pract 2020;32:15-23. [PMID: 31764399 DOI: 10.1097/JXX.0000000000000346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
38 Lyseng-Williamson KA. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use. Drugs Ther Perspect 2018;34:300-10. [PMID: 30546252 DOI: 10.1007/s40267-018-0532-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Irvine AJ, Chey WD, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112:65-76. [PMID: 27753436 DOI: 10.1038/ajg.2016.466] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
40 Chira A, Braicu C, Budisan L, Ioan Chira R, Berindan-Neagoe I, Lucian Dumitrascu D. Monocyte chemotactic protein-1 and nitrotyrosine in irritable bowel syndrome. Exp Ther Med 2020;20:24-30. [PMID: 32508988 DOI: 10.3892/etm.2020.8665] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Sood R, Camilleri M, Gracie DJ, Gold MJ, To N, Law GR, Ford AC. Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. Am J Gastroenterol 2016;111:1446-54. [PMID: 27481310 DOI: 10.1038/ajg.2016.308] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
42 Pannemans J, Vanuytsel T, Tack J. New developments in the treatment of opioid-induced gastrointestinal symptoms. United European Gastroenterol J 2018;6:1126-35. [PMID: 30288274 DOI: 10.1177/2050640618796748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Elsagh M, Fartookzadeh MR, Kamalinejad M, Anushiravani M, Feizi A, Behbahani FA, Rafiei R, Arjmandpour A, Adibi P. Efficacy of the Malva sylvestris L. flowers aqueous extract for functional constipation: A placebo-controlled trial. Complement Ther Clin Pract. 2015;21:105-111. [PMID: 25801702 DOI: 10.1016/j.ctcp.2015.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
44 Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol 2017;112:924-32. [PMID: 28417992 DOI: 10.1038/ajg.2017.72] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
45 Lacy B, Ayyagari R, Guerin A, Lopez A, Shi S, Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol 2019;12:1756284818818326. [PMID: 30636972 DOI: 10.1177/1756284818818326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Nam Y, Min YS, Sohn UD. Recent advances in pharmacological research on the management of irritable bowel syndrome. Arch Pharm Res 2018;41:955-66. [PMID: 30132170 DOI: 10.1007/s12272-018-1068-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
47 Lackner JM, Jaccard J, Radziwon CD, Firth RS, Gudleski GD, Hamilton F, Katz LA, Keefer L, Krasner SS, Ma CX, Sitrin MD, Brenner DM. Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up. Am J Gastroenterol 2019;114:330-8. [PMID: 30429592 DOI: 10.1038/s41395-018-0396-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
48 Weerts ZZRM, Keszthelyi D, Vork L, Aendekerk NCP, Frijlink HW, Brouwers JRBJ, Neef C, Jonkers DMAE, Masclee AAM. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Adv Ther 2018;35:1965-78. [PMID: 30284674 DOI: 10.1007/s12325-018-0802-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9:7-17. [PMID: 26929659 DOI: 10.2147/ijgm.s93698] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
50 Strijbos D, Keszthelyi D, Masclee AAM, Gilissen LPL. Percutaneous endoscopic colostomy for adults with chronic constipation: Retrospective case series of 12 patients. Neurogastroenterol Motil 2018;30:e13270. [DOI: 10.1111/nmo.13270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Emami Alorizi SM, Fattahi MR, Saghebi SA, Salehi A, Rezaeizadeh H, Nimrouzi M, Zarshenas MM. Assessment of the impacts of traditional Persian medical schemes and recommendations on functional chronic constipation compared to a classic medicine lactulose, a randomized clinical trial. J Complement Integr Med 2015;12:325-31. [PMID: 26214609 DOI: 10.1515/jcim-2015-0013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology 2019;4:831-44. [DOI: 10.1016/s2468-1253(19)30246-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 10.7] [Reference Citation Analysis]
53 Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations. J Am Assoc Nurse Pract 2016;28:393-404. [PMID: 27436200 DOI: 10.1002/2327-6924.12387] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
54 Keating GM. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome. Drugs 2017;77:1009-16. [DOI: 10.1007/s40265-017-0756-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
55 Losurdo G, Principi M, Iannone A, Giangaspero A, Piscitelli D, Ierardi E, Di Leo A, Barone M. Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study. Nutrients 2018;10:E2001. [PMID: 30567296 DOI: 10.3390/nu10122001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Song J, Bai T, Zhang L, Hou XH. Clinical features and treatment options among Chinese adults with self-reported constipation: An internet-based survey. J Dig Dis 2019;20:409-14. [PMID: 31145540 DOI: 10.1111/1751-2980.12792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
57 Wollny T, Daniluk T, Piktel E, Wnorowska U, Bukłaha A, Głuszek K, Durnaś B, Bucki R. Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome. Pathogens 2021;10:1545. [PMID: 34959500 DOI: 10.3390/pathogens10121545] [Reference Citation Analysis]
58 Sherwin LB. Layperson's knowledge and perceptions of irritable bowel syndrome as potential barriers to care. J Adv Nurs 2018;74:1199-207. [PMID: 29319900 DOI: 10.1111/jan.13521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Meng M, Bai C, Wan B, Zhao L, Li Z, Li D, Zhang S. A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder. Biomed Res Int 2021;2021:4579850. [PMID: 34859100 DOI: 10.1155/2021/4579850] [Reference Citation Analysis]
60 Valentin N, Acosta A, Camilleri M. Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. Expert Opin Investig Drugs 2015;24:769-79. [PMID: 25971881 DOI: 10.1517/13543784.2015.1025132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
61 Banfi D, Moro E, Bosi A, Bistoletti M, Cerantola S, Crema F, Maggi F, Giron MC, Giaroni C, Baj A. Impact of Microbial Metabolites on Microbiota-Gut-Brain Axis in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:1623. [PMID: 33562721 DOI: 10.3390/ijms22041623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Iorio N, Malik Z, Schey R. Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 2015;8:159-67. [PMID: 26089696 DOI: 10.2147/CEG.S67231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
63 Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P, Madsen KL, Surette M, Rioux JD, Dieleman LA, Verdú E, de Souza RJ, Otley A, Targownik L, Lavis J, Cunningham J, Marshall DA, Zelinsky S, Fernandes A. IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open 2020;10:e041733. [PMID: 33087380 DOI: 10.1136/bmjopen-2020-041733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Simrén M, Törnblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2017;2:112-22. [PMID: 28403981 DOI: 10.1016/S2468-1253(16)30116-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
65 Fragkos KC. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clin Exp Gastroenterol 2017;10:229-40. [PMID: 28989282 DOI: 10.2147/CEG.S123621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
66 Brugnatelli V, Turco F, Freo U, Zanette G. Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Front Neurosci 2020;14:371. [PMID: 32372912 DOI: 10.3389/fnins.2020.00371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Sheyholislami H, Connor KL. Are Probiotics and Prebiotics Safe for Use during Pregnancy and Lactation? A Systematic Review and Meta-Analysis. Nutrients 2021;13:2382. [PMID: 34371892 DOI: 10.3390/nu13072382] [Reference Citation Analysis]
68 Rajindrajith S, Devanarayana NM, Benninga MA. Constipation and Constipation-predominant Irritable Bowel Syndrome: A Comparative Study Using Rome III Criteria. Journal of Pediatric Gastroenterology & Nutrition 2017;64:679-84. [DOI: 10.1097/mpg.0000000000001332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
69 Herrick LM, Spalding WM, Saito YA, Moriarty J, Schleck C. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ 2017;20:273-9. [PMID: 27783533 DOI: 10.1080/13696998.2016.1253584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
70 Vincenzi M, Del Ciondolo I, Pasquini E, Gennai K, Paolini B. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial. J Transl Int Med. 2017;5:120-126. [PMID: 28721345 DOI: 10.1515/jtim-2017-0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
71 Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018;97:e10631. [PMID: 29768326 DOI: 10.1097/md.0000000000010631] [Cited by in Crossref: 64] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
72 Fan H, Zheng L, Lai Y, Lu W, Yan Z, Xiao Q, Li B, Tang M, Huang D, Wang Y, Li Z, Mei Y, Jiang Z, Liu X, Tang Q, Zuo D, Ye J, Yang Y, Huang H, Tang Z, Xiao J; China Irritable Bowel Syndrome Consortium. Tongxie Formula Reduces Symptoms of Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2017;15:1724-32. [PMID: 28634136 DOI: 10.1016/j.cgh.2017.06.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
73 Jiang Y, Kong H, Chang T, Bai T, Xiang X, Zhang X, Xie X, Zhang L, Zhang C, Hou X, Lin R. Modified colonic transit test in healthy subjects and constipated patients: A triple-phase, two-center prospective study. J Gastroenterol Hepatol 2021;36:959-67. [PMID: 32757482 DOI: 10.1111/jgh.15209] [Reference Citation Analysis]
74 Barmeyer C, Schumann M, Meyer T, Zielinski C, Zuberbier T, Siegmund B, Schulzke JD, Daum S, Ullrich R. Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. Int J Colorectal Dis. 2017;32:29-39. [PMID: 27695975 DOI: 10.1007/s00384-016-2663-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
75 Rao SS, Patcharatrakul T. Diagnosis and Treatment of Dyssynergic Defecation. J Neurogastroenterol Motil 2016;22:423-35. [PMID: 27270989 DOI: 10.5056/jnm16060] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 14.2] [Reference Citation Analysis]
76 Menees SB, Guentner A, Chey SW, Saad R, Chey WD. How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation? Am J Gastroenterol 2015;110:1516-25. [PMID: 26054623 DOI: 10.1038/ajg.2015.156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
77 Lin WT, Liao YJ, Peng YC, Chang CH, Lin CH, Yeh HZ, Chang CS. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J Gastroenterol 2017; 23(19): 3513-3521 [PMID: 28596687 DOI: 10.3748/wjg.v23.i19.3513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
78 Miner PB Jr. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation. Drug Saf 2019;42:603-15. [PMID: 30649746 DOI: 10.1007/s40264-018-0781-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients 2019;11:E2048. [PMID: 31480656 DOI: 10.3390/nu11092048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
80 Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol 2018;11:335-45. [PMID: 30288076 DOI: 10.2147/CEG.S167031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
81 Chen Y, Ding Z, Wu Y, Chen Q, Liu M, Yu H, Wang D, Zhang Y, Wang T. Effects of Allium mongolicum Regel and Its Flavonoids on Constipation. Biomolecules 2019;10:E14. [PMID: 31877639 DOI: 10.3390/biom10010014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
82 Baker DE. Formulary Drug Reviews: Plecanatide. Hosp Pharm 2017;52:400-5. [PMID: 29276262 DOI: 10.1177/0018578717717623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
83 Cozma-Petruţ A, Loghin F, Miere D, Dumitraşcu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol 2017; 23(21): 3771-3783 [PMID: 28638217 DOI: 10.3748/wjg.v23.i21.3771] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 36] [Article Influence: 10.4] [Reference Citation Analysis]
84 Capili B, Anastasi JK, Chang M. Addressing the Role of Food in Irritable Bowel Syndrome Symptom Management. J Nurse Pract. 2016;12:324-329. [PMID: 27429601 DOI: 10.1016/j.nurpra.2015.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
85 Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SS, Ma CX, Radziwon CD, Sitrin MD. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. Gastroenterology 2018;155:47-57. [PMID: 29702118 DOI: 10.1053/j.gastro.2018.03.063] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 16.8] [Reference Citation Analysis]
86 Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
87 Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, Simrén M, Lembo A, Young-Fadok TM, Chang L. Chronic constipation. Nat Rev Dis Primers 2017;3:17095. [PMID: 29239347 DOI: 10.1038/nrdp.2017.95] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 16.8] [Reference Citation Analysis]
88 Quigley EM, Neshatian L. Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother. 2016;17:501-511. [PMID: 26630260 DOI: 10.1517/14656566.2016.1127356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
89 Andrews CN, Sidani S, Marshall JK. Clinical Management of the Microbiome in Irritable Bowel Syndrome. J Can Assoc Gastroenterol 2021;4:36-43. [PMID: 33644675 DOI: 10.1093/jcag/gwz037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
90 Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018;60:213-222. [PMID: 30257542 DOI: 10.23736/s0031-0808.18.03541-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
91 Draper K, Ley C, Parsonnet J. Probiotic guidelines and physician practice: a cross-sectional survey and overview of the literature. Beneficial Microbes 2017;8:507-19. [DOI: 10.3920/bm2016.0146] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
92 Gong BY, Ma HM, Zang XY, Wang SY, Zhang Y, Jiang N, Zhang XP, Zhao Y. Efficacy of Cranial Electrotherapy Stimulation Combined with Biofeedback Therapy in Patients with Functional Constipation. J Neurogastroenterol Motil 2016;22:497-508. [PMID: 26932836 DOI: 10.5056/jnm15089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
93 Tse Y, Armstrong D, Andrews CN, Bitton A, Bressler B, Marshall J, Liu LW. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Can J Gastroenterol Hepatol 2017;2017:8612189. [PMID: 28271055 DOI: 10.1155/2017/8612189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
94 Lacy BE. Review article: An analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:817-830. [PMID: 30194692 DOI: 10.1111/apt.14948] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
95 Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther 2018;35:289-310. [PMID: 29498019 DOI: 10.1007/s12325-018-0673-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 17.8] [Reference Citation Analysis]
96 Deb B, Prichard DO, Bharucha AE. Constipation and Fecal Incontinence in the Elderly. Curr Gastroenterol Rep 2020;22:54. [PMID: 32839874 DOI: 10.1007/s11894-020-00791-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
97 Varjú P, Gede N, Szakács Z, Hegyi P, Cazacu IM, Pécsi D, Fábián A, Szepes Z, Vincze Á, Tenk J, Balaskó M, Rumbus Z, Garami A, Csupor D, Czimmer J. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil 2019;31:e13527. [PMID: 30560578 DOI: 10.1111/nmo.13527] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
98 Pimentel M, Purdy C, Magar R, Rezaie A. A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. Clin Ther 2016;38:1638-1652.e9. [PMID: 27261204 DOI: 10.1016/j.clinthera.2016.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
99 Sharma A, Herekar AA, Bhagatwala J, Rao SS. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. Clin Exp Gastroenterol 2019;12:31-6. [PMID: 30774407 DOI: 10.2147/CEG.S145668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
100 Yu FT, Long DH, Shi GX, Wang LQ, Tu JF, Gang LL, Liu FQ, Wang Y, Cui X, Bao S, Yu Y, Wei W, Yan SY, Yang JW, Liu CZ. Evaluating the efficacy and safety of electro-acupuncture in patients with antipsychotic-related constipation: protocol for a randomized controlled trial. Trials 2021;22:771. [PMID: 34736504 DOI: 10.1186/s13063-021-05732-5] [Reference Citation Analysis]
101 Aziz I, Whitehead WE, Palsson OS, Törnblom H, Simrén M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol 2020;14:39-46. [PMID: 31893959 DOI: 10.1080/17474124.2020.1708718] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
102 Lacy BE, Shea EP, Manuel M, Abel JL, Jiang H, Taylor DCA. Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications. PLoS One 2021;16:e0243318. [PMID: 33428631 DOI: 10.1371/journal.pone.0243318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Kane JS, Irvine AJ, Derwa Y, Rotimi O, Ford AC. High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. Therap Adv Gastroenterol 2018;11:1756284818783600. [PMID: 29977339 DOI: 10.1177/1756284818783600] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
104 Quigley EMM. Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome - possible and important? Aliment Pharmacol Ther 2015;41:1299-1299. [DOI: 10.1111/apt.13208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
105 Pannemans J, Masuy I, Tack J. Functional Constipation: Individualising Assessment and Treatment. Drugs 2020;80:947-63. [PMID: 32451924 DOI: 10.1007/s40265-020-01305-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Barberio B, Judge C, Savarino EV, Ford AC. Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:638-48. [PMID: 34090581 DOI: 10.1016/S2468-1253(21)00111-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Luo D, Qu C, Zhang Z, Xie J, Xu L, Yang H, Li C, Lin G, Wang H, Su Z. Granularity and Laxative Effect of Ultrafine Powder of Dendrobium officinale. Journal of Medicinal Food 2017;20:180-8. [DOI: 10.1089/jmf.2016.3827] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
108 Pisipati S, Connor BA, Riddle MS. Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome. Curr Opin Infect Dis. 2020;33:411-418. [PMID: 32833689 DOI: 10.1097/qco.0000000000000666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Harris LA. Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy. Dig Dis Sci 2016;61:334-6. [DOI: 10.1007/s10620-015-4004-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
110 Mirghafourvand M, Homayouni Rad A, Mohammad Alizadeh Charandabi S, Fardiazar Z, Shokri K. The Effect of Probiotic Yogurt on Constipation in Pregnant Women: A Randomized Controlled Clinical Trial. Iran Red Crescent Med J 2016;18:e39870. [PMID: 28203450 DOI: 10.5812/ircmj.39870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
111 Sumida K, Dashputre AA, Potukuchi PK, Thomas F, Obi Y, Molnar MZ, Gatwood JD, Streja E, Kalantar-Zadeh K, Kovesdy CP. Laxative use in patients with advanced chronic kidney disease transitioning to dialysis. Nephrol Dial Transplant 2020:gfaa205. [PMID: 33035325 DOI: 10.1093/ndt/gfaa205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. [PMID: 27159638 DOI: 10.1038/nrdp.2016.14] [Cited by in Crossref: 338] [Cited by in F6Publishing: 292] [Article Influence: 56.3] [Reference Citation Analysis]
113 Juncadella AC, Moss A. Fecal microbiota transplantation as a possible treatment of irritable bowel syndrome. Ann Transl Med 2017;5:506. [PMID: 29299467 DOI: 10.21037/atm.2017.09.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
114 Guerreiro MM, Santos Z, Carolino E, Correa J, Cravo M, Augusto F, Chagas C, Guerreiro CS. Effectiveness of Two Dietary Approaches on the Quality of Life and Gastrointestinal Symptoms of Individuals with Irritable Bowel Syndrome. J Clin Med 2020;9:E125. [PMID: 31906563 DOI: 10.3390/jcm9010125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
115 Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23(36): 6593-6627 [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6593] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
116 Sayuk GS, Wolf R, Chang L. Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol 2017;112:892-9. [PMID: 28094313 DOI: 10.1038/ajg.2016.574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
117 Remes-Troche JM, Coss-Adame E, Lopéz-Colombo A, Amieva-Balmori M, Carmona Sánchez R, Charúa Guindic L, Flores Rendón R, Gómez Escudero O, González Martínez M, Icaza Chávez ME, Morales Arámbula M, Schmulson M, Tamayo de la Cuesta JL, Valdovinos MÁ, Vázquez Elizondo G. The Mexican consensus on chronic constipation. Rev Gastroenterol Mex (Engl Ed) 2018;83:168-89. [PMID: 29555103 DOI: 10.1016/j.rgmx.2017.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196-208. [PMID: 28274108 DOI: 10.5009/gnl16126] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
119 Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9:7-17. [PMID: 26929659 DOI: 10.2147/ijgm] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
120 El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2015;9:1161-74. [PMID: 26162959 DOI: 10.1586/17474124.2015.1067138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
121 Abdel-hamid MS, Anis A, Elbawab RH, Mohammed AAB, Orabi SH, Fathalla SI. Distinctive antagonistic role of new Enterococcus faecium ER-3M strain and its bacteriocin effect against Staphylococcus aureus Pneumonia. Rend Fis Acc Lincei 2018;29:675-90. [DOI: 10.1007/s12210-018-0722-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
122 Qi Q, Zhang Y, Chen F, Zuo X, Li Y. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol 2018;18:5. [PMID: 29310568 DOI: 10.1186/s12876-017-0734-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
123 Camilleri M, Ford AC. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.Handb Exp Pharmacol. 2017;239:75-113. [PMID: 27995391 DOI: 10.1007/164_2016_102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
124 Wong MYW, Hebbard G, Gibson PR, Burgell RE. Chronic constipation and abdominal pain: Independent or closely interrelated symptoms? J Gastroenterol Hepatol 2020;35:1294-301. [PMID: 31900961 DOI: 10.1111/jgh.14970] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
125 Bennett WE Jr. Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease. Drug Saf 2016;39:295-305. [PMID: 26467550 DOI: 10.1007/s40264-015-0349-x] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
126 Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2017;45:14-26. [PMID: 27910150 DOI: 10.1111/apt.13839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
127 Luthra P, Burr NE, Brenner DM, Ford AC. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. Gut 2019;68:434-44. [PMID: 29730600 DOI: 10.1136/gutjnl-2018-316001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
128 Jarde A, Lewis-Mikhael AM, Moayyedi P, Stearns JC, Collins SM, Beyene J, McDonald SD. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2018;18:14. [PMID: 29310610 DOI: 10.1186/s12884-017-1629-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 10.5] [Reference Citation Analysis]
129 Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci. 2016;61:560-571. [PMID: 26319955 DOI: 10.1007/s10620-015-3858-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 11.1] [Reference Citation Analysis]
130 Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clin Transl Gastroenterol. 2015;6:e107. [PMID: 26291435 DOI: 10.1038/ctg.2015.21] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
131 Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients 2020;12:E363. [PMID: 32019158 DOI: 10.3390/nu12020363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
132 Bielefeldt K, Levinthal DJ, Nusrat S. Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis. J Neurogastroenterol Motil 2016;22:31-45. [PMID: 26717930 DOI: 10.5056/jnm15171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
133 Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis 2018;50:741-9. [PMID: 29807873 DOI: 10.1016/j.dld.2018.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
134 Martinez de Andino N. Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. J Am Assoc Nurse Pract 2018;30:412-20. [PMID: 29979299 DOI: 10.1097/JXX.0000000000000090] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580-587. [PMID: 25781368 DOI: 10.1038/ajg.2015.67] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 10.7] [Reference Citation Analysis]
136 Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F. Advancements in drug development for diarrhea-predominant irritable bowel syndrome. Expert Opin Investig Drugs 2018;27:251-63. [PMID: 29451407 DOI: 10.1080/13543784.2018.1442434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Thomas A, Quigley EM. Diet and irritable bowel syndrome: . Current Opinion in Gastroenterology 2015;31:166-71. [DOI: 10.1097/mog.0000000000000158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
138 Corsetti M, Pannemans J, Whorwell P. Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders? F1000Res 2019;8:F1000 Faculty Rev-257. [PMID: 30863534 DOI: 10.12688/f1000research.15974.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, Emmanuel A, Hungin APS, Layer P, Stanghellini V, Whorwell P, Zerbib F, Tack J. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J. 2017;5:773-788. [PMID: 29026591 DOI: 10.1177/2050640617731968] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
140 Jin S, Li YF, Qin D, Luo DQ, Guo H, Gao XH, Yue L, Zheng H. Non-pharmacological treatments for irritable bowel syndrome: study protocol of an umbrella review of systematic review and meta-analyses. BMJ Open 2019;9:e027778. [PMID: 30898835 DOI: 10.1136/bmjopen-2018-027778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
141 Corsetti M, Brown S, Chiarioni G, Dimidi E, Dudding T, Emmanuel A, Fox M, Ford AC, Giordano P, Grossi U, Henderson M, Knowles CH, O'Connell PR, Quigley EMM, Simren M, Spiller R, Whelan K, Whitehead WE, Williams AB, Scott SM. Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterol Motil 2021;33:e14070. [PMID: 33522079 DOI: 10.1111/nmo.14070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Ortega MV, Kim Y, Hung K, James K, Savitt L, Von Bargen E, Bordeianou LG, Weinstein MM. Women with chronic constipation have more bothersome urogenital symptoms. Tech Coloproctol 2022;26:29-34. [PMID: 34820751 DOI: 10.1007/s10151-021-02518-4] [Reference Citation Analysis]
143 Wasilewski A, Misicka A, Sacharczuk M, Fichna J. Prosecretory effect of loperamide in ileal and colonic mucosae of mice displaying high or low swim stress-induced analgesia associated with high and low endogenous opioid system activity. Neurogastroenterol Motil 2018;30:e13166. [DOI: 10.1111/nmo.13166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
144 Rao SSC, Lichtlen P, Habibi S. Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation. J Clin Gastroenterol 2021;55:512-9. [PMID: 32569031 DOI: 10.1097/MCG.0000000000001385] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Rivkin A, Rybalov S. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline. Pharmacotherapy 2016;36:300-16. [DOI: 10.1002/phar.1712] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
146 Vazquez Roque M, Bouras EP. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;10:919-930. [PMID: 26082622 DOI: 10.2147/cia.s54304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
147 Streicher JM, Bilsky EJ. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications. J Pharm Pract 2018;31:658-69. [PMID: 28946783 DOI: 10.1177/0897190017732263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
148 Bharucha AE, Chakraborty S, Sletten CD. Common Functional Gastroenterological Disorders Associated With Abdominal Pain. Mayo Clin Proc 2016;91:1118-32. [PMID: 27492916 DOI: 10.1016/j.mayocp.2016.06.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
149 Niesen CR, Olson DM, Nowdesha KD, Tynsky DA, Loftus CG, Meiers SJ. Enhancing Self-management for Adults With Functional Abdominal Pain: A Registered Nurse-Led Cognitive-Behavioral Therapy Approach. Gastroenterology Nursing 2018;41:321-32. [DOI: 10.1097/sga.0000000000000322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
150 Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1149-72.e2. [PMID: 25224525 DOI: 10.1053/j.gastro.2014.09.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 9.9] [Reference Citation Analysis]
151 Goldenberg JZ, Steel A, Day A, Yap C, Bradley R, Cooley K. Naturopathic approaches to irritable bowel syndrome: protocol for a prospective observational study in academic teaching clinics. Integr Med Res 2018;7:279-86. [PMID: 30271717 DOI: 10.1016/j.imr.2018.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Mari A, Mahamid M, Amara H, Baker FA, Yaccob A. Chronic Constipation in the Elderly Patient: Updates in Evaluation and Management. Korean J Fam Med 2020;41:139-45. [PMID: 32062960 DOI: 10.4082/kjfm.18.0182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
153 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG. [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)]. Aten Primaria 2017;49:177-94. [PMID: 28238460 DOI: 10.1016/j.aprim.2017.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol 2019;35:58-62. [PMID: 30407259 DOI: 10.1097/MOG.0000000000000493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
155 Sommers T, Corban C, Sengupta N, Jones M, Cheng V, Bollom A, Nurko S, Kelley J, Lembo A. Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol. 2015;110:572-579. [PMID: 25803399 DOI: 10.1038/ajg.2015.64] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
156 Portincasa P, Bonfrate L, de Bari O, Lembo A, Ballou S. Irritable bowel syndrome and diet. Gastroenterol Rep (Oxf). 2017;5:11-19. [PMID: 28110300 DOI: 10.1093/gastro/gow047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
157 Christodoulides S, Dimidi E, Fragkos KC, Farmer AD, Whelan K, Scott SM. Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults. Aliment Pharmacol Ther 2016;44:103-16. [PMID: 27170558 DOI: 10.1111/apt.13662] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
158 Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs 2020;43:E102-22. [PMID: 32487960 DOI: 10.1097/SGA.0000000000000530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
159 Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2017;174:1426-49. [PMID: 27696378 DOI: 10.1111/bph.13632] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 10.5] [Reference Citation Analysis]
160 Thorkelson G, Bielefeldt K, Szigethy E. Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD: . Inflammatory Bowel Diseases 2016;22:1509-22. [DOI: 10.1097/mib.0000000000000734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
161 Kane JS, Ford AC. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2016;10:431-42. [PMID: 26753693 DOI: 10.1586/17474124.2016.1140571] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
162 Quach DT, Hiyama T, Nguyen TA, Ly HQ, Tanaka S. Asia-Pacific Colorectal Screening score: A useful tool to stratify risk for colorectal advanced neoplasms in Vietnamese patients with irritable bowel syndrome: APCS score to predict colorectal neoplasms in IBS. Journal of Gastroenterology and Hepatology 2018;33:150-5. [DOI: 10.1111/jgh.13821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
163 Crosby EC, Husk KE. Defecatory Dysfunction. Obstet Gynecol Clin North Am 2021;48:653-63. [PMID: 34416943 DOI: 10.1016/j.ogc.2021.05.016] [Reference Citation Analysis]
164 Liang S, Liang C, Yang S, Li Y, Tian Z, Robinson N, Liu J. Clinical effects and safety of Compound Glutamine Entersoluble Capsules for diarrhea-predominant irritable bowel syndrome: A systematic review and meta-analysis. European Journal of Integrative Medicine 2019;32:101005. [DOI: 10.1016/j.eujim.2019.101005] [Reference Citation Analysis]
165 Li P, Shen M, Lou GC, Chen YW, Wu WQ. Meta-analysis of mesalazine for irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2015; 23(30): 4911-4918 [DOI: 10.11569/wcjd.v23.i30.4911.] [Reference Citation Analysis]
166 Portincasa P, Lembo A, de Bari O, Di Palo DM, Maggio A, Cataldo I, Calamita G. The Role of Dietary Approach in Irritable Bowel Syndrome. Curr Med Chem 2019;26:3512-20. [PMID: 28462704 DOI: 10.2174/0929867324666170428102451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
167 Austhof E, Schaefer K, Faulkner J, Bach L, Riddle M, Pogreba-Brown K. Knowledge and practices of primary care physicians or general practitioners treating post-infectious Irritable Bowel Syndrome. BMC Gastroenterol 2020;20:159. [PMID: 32450813 DOI: 10.1186/s12876-020-01305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Lei S, Yuan L. Rice Bran Usage in Diarrhea. Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019. pp. 257-63. [DOI: 10.1016/b978-0-12-814468-8.00021-1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Kamp EJ, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14:659-668.e1; quiz e54-55. [PMID: 26453949 DOI: 10.1016/j.cgh.2015.09.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
170 Nelson AD, Camilleri M, Acosta A, Boldingh A, Busciglio I, Burton D, Ryks M, Zinsmeister AR. A single-center, prospective, double-blind, sham-controlled, randomized study of the effect of a vibrating capsule on colonic transit in patients with chronic constipation. Neurogastroenterol Motil 2017;29. [PMID: 28177172 DOI: 10.1111/nmo.13034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
171 Losurdo G, Giorgio F, Piscitelli D, Montenegro L, Covelli C, Fiore MG, Giangaspero A, Iannone A, Principi M, Amoruso A, Barone M, Di Leo A, Ierardi E. May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? World J Gastroenterol 2016; 22(35): 8017-8025 [PMID: 27672296 DOI: 10.3748/wjg.v22.i35.8017] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
172 Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology. 2019;157:859-880. [PMID: 31351880 DOI: 10.1053/j.gastro.2019.06.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
173 Weaver KR, Melkus GD, Henderson WA. Irritable Bowel Syndrome. Am J Nurs 2017;117:48-55. [PMID: 28541989 DOI: 10.1097/01.NAJ.0000520253.57459.01] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
174 Patel S, Doerfler B, Boutros K, Ng S, Manuel M, DeSimone E. Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation. Int J Gen Med 2021;14:1457-68. [PMID: 33907450 DOI: 10.2147/IJGM.S274568] [Reference Citation Analysis]
175 Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9:354-75. [PMID: 27134665 DOI: 10.1177/1756283X16633050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
176 Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2019;2:6-29. [PMID: 31294724 DOI: 10.1093/jcag/gwy071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
177 Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, Lim HC, Shin JE, Kim SE, Cho DH, Kim JH, Kim HJ; Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24:197-215. [PMID: 29605976 DOI: 10.5056/jnm17145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
178 Mascolo M, Mcbride J, Mehler PS. Effective medical treatment strategies to help cessation of purging behaviors: STRATEGIES TO HELP CESSATION OF PURGING BEHAVIORS. Int J Eat Disord 2016;49:324-30. [DOI: 10.1002/eat.22500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
179 Ford AC. Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive-Behavioral Therapy. Gastroenterology 2018;155:2024. [PMID: 30240662 DOI: 10.1053/j.gastro.2018.05.054] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Ozaki K, Maruo T, Kosaka H, Mori M, Mori H, Yamori Y, Toda T. The effects of fermented milk containing Lactococcus lactis subsp. cremoris FC on defaecation in healthy young Japanese women: a double-blind, placebo-controlled study. International Journal of Food Sciences and Nutrition 2018;69:762-9. [DOI: 10.1080/09637486.2017.1417977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
181 Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016; Epub ahead of print. [PMID: 27144621 DOI: 10.1053/j.gastro.2016.02.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
182 Hayat M, Zia H, Nusrat S. Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes. Patient Relat Outcome Meas 2019;10:43-7. [PMID: 30858742 DOI: 10.2147/PROM.S157905] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
183 Wu IXY, Wong CHL, Ho RST, Cheung WKW, Ford AC, Wu JCY, Mak ADP, Cramer H, Chung VCH. Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol. 2019;12:1756284818820438. [PMID: 30719074 DOI: 10.1177/1756284818820438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
184 Cash BD, Lacy BE, Rao T, Earnest DL. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother 2016;17:311-22. [PMID: 26559529 DOI: 10.1517/14656566.2016.1118052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
185 Quigley EMM, Horn J, Kissous-hunt M, Crozier RA, Harris LA. Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. Adv Ther 2018;35:967-80. [DOI: 10.1007/s12325-018-0733-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
186 Yu J, Qian YY, He CH, Zhu SG, Zhao AJ, Zhu QQ, Shao CW, Wang TG, Wang Y, Ding GL, Liao Z, Li ZS. Safety and Efficacy of a New Smartphone-controlled Vibrating Capsule on Defecation in Beagles. Sci Rep 2017;7:2841. [PMID: 28588191 DOI: 10.1038/s41598-017-02844-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
187 Mazzawi T, El-Salhy M. Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (Review). Int J Mol Med 2017;40:943-52. [PMID: 28849091 DOI: 10.3892/ijmm.2017.3096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
188 Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27:705-716. [PMID: 25809913 DOI: 10.1111/nmo.12544] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
189 Bharucha AE, Wald A. Chronic Constipation. Mayo Clin Proc. 2019;94:2340-2357. [PMID: 31054770 DOI: 10.1016/j.mayocp.2019.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
190 Pont LG, Fisher M, Williams K. Appropriate Use of Laxatives in the Older Person. Drugs Aging 2019;36:999-1005. [PMID: 31478168 DOI: 10.1007/s40266-019-00701-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
191 Harris LA, Umar SB, Baffy N, Heitkemper MM. Irritable Bowel Syndrome and Female Patients. Gastroenterol Clin North Am 2016;45:179-204. [PMID: 27261893 DOI: 10.1016/j.gtc.2016.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
192 Wang Y, Fan H, Qi X, Lai Y, Yan Z, Li B, Tang M, Huang D, Li Z, Chen H, Zhu Q, Luo C, Chen X, Fen J, Jiang Z, Zheng L, Liu X, Tang Q, Zuo D, Ye J, Yang Y, Huang H, Tang Z, Lu W, Xiao J; Pharm D for the China Irritable Bowel Syndrome Consortium. Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trial. Complement Ther Med 2018;40:95-105. [PMID: 30219477 DOI: 10.1016/j.ctim.2018.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
193 Lee YY, Annamalai C, Rao SSC. Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0595-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
194 Gwee KA, Gonlachanvit S, Ghoshal UC, Chua ASB, Miwa H, Wu J, Bak YT, Lee OY, Lu CL, Park H, Chen M, Syam AF, Abraham P, Sollano J, Chang CS, Suzuki H, Fang X, Fukudo S, Choi MG, Hou X, Hongo M. Second Asian Consensus on Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2019;25:343-362. [PMID: 31327218 DOI: 10.5056/jnm19041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
195 Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology & Hepatology 2016;1:133-46. [DOI: 10.1016/s2468-1253(16)30023-1] [Cited by in Crossref: 171] [Cited by in F6Publishing: 75] [Article Influence: 28.5] [Reference Citation Analysis]
196 Rao VL, Micic D, Kim KE. Primary Care Evaluation and Management of Gastroenterologic Issues in Women. Obstet Gynecol Clin North Am 2016;43:347-66. [PMID: 27212096 DOI: 10.1016/j.ogc.2016.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
197 Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Rep 2020;5:121-34. [PMID: 32043026 DOI: 10.1016/j.ekir.2019.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
198 Brown K, Scott-Hoy B, Jennings LW. Response of irritable bowel syndrome with constipation patients administered a combined quebracho/conker tree/M. balsamea Willd extract. World J Gastrointest Pharmacol Ther 2016; 7(3): 463-468 [PMID: 27602249 DOI: 10.4292/wjgpt.v7.i3.463] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
199 Brenner DM, Shah M. Chronic Constipation. Gastroenterol Clin North Am 2016;45:205-16. [PMID: 27261894 DOI: 10.1016/j.gtc.2016.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
200 Bardisi BM, Halawani AKH, Halawani HKH, Alharbi AH, Turkostany NS, Alrehaili TS, Radin AA, Alkhuzea NM. Efficiency of diet change in irritable bowel syndrome. J Family Med Prim Care. 2018;7:946-951. [PMID: 30598938 DOI: 10.4103/jfmpc.jfmpc_173_18] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
201 Marlicz W, Yung DE, Skonieczna-Żydecka K, Loniewski I, van Hemert S, Loniewska B, Koulaouzidis A. From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases. Expert Rev Gastroenterol Hepatol 2017;11:961-78. [PMID: 28618973 DOI: 10.1080/17474124.2017.1343664] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
202 Brenner DM, Dove LS, Andrae DA, Covington PS, Gutman C, Chey WD. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil 2018;30:e13331. [DOI: 10.1111/nmo.13331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
203 Kim SJ, Park KS. [Pharmacotherapy in Patients with Chronic Constipation]. Korean J Gastroenterol 2017;70:64-71. [PMID: 28830131 DOI: 10.4166/kjg.2017.70.2.64] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
204 Rijnaarts I, Witteman BJM, Zoetendal EG, Govers C, de Wit NJW, de Roos NM. Subtypes and Severity of Irritable Bowel Syndrome Are Not Related to Patients' Self-Reported Dietary Triggers: Results From an Online Survey in Dutch Adults. J Acad Nutr Diet 2021;121:1750-1762.e8. [PMID: 33674208 DOI: 10.1016/j.jand.2021.01.007] [Reference Citation Analysis]
205 Omer A, Quigley EMM. An update on prucalopride in the treatment of chronic constipation. Therap Adv Gastroenterol 2017;10:877-87. [PMID: 29147138 DOI: 10.1177/1756283X17734809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 9] [Article Influence: 7.2] [Reference Citation Analysis]
206 Gupta K, Ghuman HS, Handa SV. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clin Med Insights Gastroenterol 2017;10:1179552217728905. [PMID: 28894393 DOI: 10.1177/1179552217728905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
207 Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Current Opinion in Endocrinology, Diabetes & Obesity 2020;27:28-35. [DOI: 10.1097/med.0000000000000523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
208 Zhang X, Tian H, Gu L, Nie Y, Ding C, Ge X, Yang B, Gong J, Li N. Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. Sci China Life Sci 2018;61:779-86. [PMID: 29441452 DOI: 10.1007/s11427-017-9229-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
209 Daghaghzadeh H, Memar A, Mohamadi Y, Rezakhani N, Safazadeh P, Aghaha S, Adibi P. Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract 2018;7:13-21. [PMID: 29755994 DOI: 10.4103/jrpp.JRPP_17_56] [Reference Citation Analysis]
210 Dong Y, Baumeister D, Berens S, Eich W, Tesarz J. High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary Care. Front Psychiatry 2019;10:714. [PMID: 31681031 DOI: 10.3389/fpsyt.2019.00714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
211 Özdener AE, Rivkin A. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Drug Des Devel Ther 2017;11:2827-40. [PMID: 29033544 DOI: 10.2147/DDDT.S127405] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
212 Thomas RH, Luthin DR. Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: Focus on Prosecretory Agents. Pharmacotherapy 2015;35:613-30. [DOI: 10.1002/phar.1594] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
213 Ong AML. Utility of gastrointestinal ultrasound in functional gastrointestinal disorders: A narrative review. World J Meta-Anal 2020; 8(2): 109-118 [DOI: 10.13105/wjma.v8.i2.109] [Reference Citation Analysis]
214 Zhang FM, Li S, Ding L, Xiang SH, Zhu HT, Yu JH, Xu GQ. Effectiveness of mesalazine to treat irritable bowel syndrome: A meta-analysis. Medicine (Baltimore) 2019;98:e16297. [PMID: 31305414 DOI: 10.1097/MD.0000000000016297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
215 Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256-1270. [PMID: 25903636 DOI: 10.1111/apt.13167] [Cited by in Crossref: 159] [Cited by in F6Publishing: 124] [Article Influence: 22.7] [Reference Citation Analysis]
216 Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 2019;35:461-72. [DOI: 10.1080/03007995.2018.1533456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
217 Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;. [PMID: 27144627 DOI: 10.1053/j.gastro.2016.02.031] [Cited by in Crossref: 1039] [Cited by in F6Publishing: 643] [Article Influence: 173.2] [Reference Citation Analysis]
218 Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol 2017;10:727-36. [PMID: 28932273 DOI: 10.1177/1756283X17718677] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
219 Whitehead WE, Palsson OS, Simrén M. Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. Neurogastroenterol Motil 2016;28:783-92. [PMID: 27214096 DOI: 10.1111/nmo.12852] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
220 Chachu KA, Osterman MT. How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. Inflamm Bowel Dis 2016;22:1262-74. [PMID: 26891261 DOI: 10.1097/MIB.0000000000000726] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
221 Reuzé A, Delvert R, Perrin L, Benamouzig R, Sabaté JM, Bouchoucha M, Allès B, Touvier M, Hercberg S, Julia C, Kesse-Guyot E. Association between Self-Reported Gluten Avoidance and Irritable Bowel Syndrome: Findings of the NutriNet-Santé Study. Nutrients 2021;13:4147. [PMID: 34836402 DOI: 10.3390/nu13114147] [Reference Citation Analysis]
222 Fattahi M, Alorizi SE, Nimrouzi M, Zarshenas M, Parvizi M. A randomized clinical trial on treatment of chronic constipation by traditional persian medicine recommendations compared to allopathic medicine: A pilot study. Int J Prev Med 2017;8:50. [DOI: 10.4103/ijpvm.ijpvm_302_16] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
223 Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.19.02567-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
224 Kikuchi S, Oe Y, Sasaki Y, Ishii H, Ito Y, Horikoshi M, Sozu T, Seno H, Furukawa TA. Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial. BMC Gastroenterol 2020;20:29. [PMID: 32019509 DOI: 10.1186/s12876-020-1157-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Shah SL, Lacy BE. Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence. Curr Gastroenterol Rep. 2016;18:41. [PMID: 27372289 DOI: 10.1007/s11894-016-0517-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
226 Andrews CN, Bradette M. Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update. J Can Assoc Gastroenterol 2020;3:e37-48. [PMID: 33241185 DOI: 10.1093/jcag/gwz034] [Reference Citation Analysis]
227 Lacy BE. The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2015;13:1899-906. [PMID: 25769411 DOI: 10.1016/j.cgh.2015.02.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
228 Hu L, Ku F, Lu T, Shen C, Hu Y, Yeh C, Tzeng C, Chen T, Chen P, Liu C. Risk of cancer in patients with irritable bowel syndrome: a nationwide population-based study. Annals of Epidemiology 2015;25:924-8. [DOI: 10.1016/j.annepidem.2015.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
229 Serra J, Mascort-roca J, Marzo-castillejo M, Aros SD, Ferrándiz Santos J, Rey Diaz Rubio E, Mearin Manrique F. Guía de práctica clínica sobre el manejo del estreñimiento crónico en el paciente adulto. Parte 2: Diagnóstico y tratamiento. Gastroenterología y Hepatología 2017;40:303-16. [DOI: 10.1016/j.gastrohep.2016.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
230 Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ 2017;20:353-62. [PMID: 27919177 DOI: 10.1080/13696998.2016.1269016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
231 Khalighi Sikaroudi M, Mokhtare M, Shidfar F, Janani L, Faghihi Kashani A, Masoodi M, Agah S, Dehnad A, Shidfar S. Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. EXCLI J 2020;19:652-67. [PMID: 33013260 DOI: 10.17179/excli2020-2247] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
232 Yue L, Chen M, Tang TC, She TW, Chen YY, Zheng H. Comparative effectiveness of pharmacological treatments for patients with diarrhea-predominant irritable bowel syndrome: Protocol of a systematic review and network meta-analysis. Medicine (Baltimore) 2018;97:e11682. [PMID: 30075562 DOI: 10.1097/MD.0000000000011682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Mizock BA. Probiotics. Disease-a-Month 2015;61:259-90. [DOI: 10.1016/j.disamonth.2015.03.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
234 Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2016;10:807-15. [PMID: 26907518 DOI: 10.1586/17474124.2016.1158099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
235 Talley NJ. Board Review Vignette: Irritable Bowel Syndrome. Am J Gastroenterol 2016;111:1223-5. [PMID: 27527743 DOI: 10.1038/ajg.2016.317] [Reference Citation Analysis]
236 Chey SW, Chey WD, Jackson K, Eswaran S. Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation. Am J Gastroenterol 2021;116:1304-12. [PMID: 34074830 DOI: 10.14309/ajg.0000000000001149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
237 Jones J, Lembo A, Heidelbaugh J, Kuritzky L, Lacy B. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. Curr Med Res Opin 2021;37:567-78. [PMID: 33566707 DOI: 10.1080/03007995.2021.1888705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Stern EK, Brenner DM. Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2018;9:e134. [PMID: 29446765 DOI: 10.1038/ctg.2018.2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
239 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort J, Peña E, Cañones P, Júdez J. Guía de práctica clínica del síndrome del intestino irritable con estreñimiento y estreñimiento funcional en adultos: tratamiento. (Parte 2 de 2). SEMERGEN - Medicina de Familia 2017;43:123-40. [DOI: 10.1016/j.semerg.2017.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
240 Sumida K, Dashputre AA, Potukuchi PK, Thomas F, Obi Y, Molnar MZ, Gatwood JD, Streja E, Kalantar-Zadeh K, Kovesdy CP. Laxative Use and Change in Estimated Glomerular Filtration Rate in Patients With Advanced Chronic Kidney Disease. J Ren Nutr 2021;31:361-9. [PMID: 32952006 DOI: 10.1053/j.jrn.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
241 Virtanen T, Eskelinen S, Sailas E, Suvisaari J. Dyspepsia and constipation in patients with schizophrenia spectrum disorders. Nordic Journal of Psychiatry 2016;71:48-54. [DOI: 10.1080/08039488.2016.1217044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
242 Nigam GB, Limdi JK, Vasant DH. Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818816956. [PMID: 30574193 DOI: 10.1177/1756284818816956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
243 Qi Z, Middleton JW, Malcolm A. Bowel Dysfunction in Spinal Cord Injury. Curr Gastroenterol Rep. 2018;20:47. [PMID: 30159690 DOI: 10.1007/s11894-018-0655-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
244 Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, Hungin APS, Layer P, Mendive JM, Pfeifer J, Rogler G, Scott SM, Simrén M, Whorwell P; Functional Constipation Guidelines Working Group. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterol Motil 2020;32:e13762. [PMID: 31756783 DOI: 10.1111/nmo.13762] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
245 Caballero N, Benslaiman B, Ansell J, Serra J. The effect of green kiwifruit on gas transit and tolerance in healthy humans. Neurogastroenterol Motil 2020;32:e13874. [PMID: 32431019 DOI: 10.1111/nmo.13874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ferreira AI, Garrido M, Castro-Poças F. Irritable Bowel Syndrome: News from an Old Disorder. GE Port J Gastroenterol 2020;27:255-68. [PMID: 32775547 DOI: 10.1159/000503757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
247 Mansueto P, D’Alcamo A, Seidita A, Carroccio A. Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity. World J Gastroenterol 2015; 21(23): 7089-7109 [PMID: 26109796 DOI: 10.3748/wjg.v21.i23.7089] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
248 Corsetti M, Whorwell P. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline. Expert Rev Gastroenterol Hepatol 2017;11:285-92. [PMID: 28276811 DOI: 10.1080/17474124.2017.1298442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
249 Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 2016; 7(1): 78-90 [PMID: 26855814 DOI: 10.4292/wjgpt.v7.i1.78] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
250 Nag A, Martin SA, Mladsi D, Olayinka-Amao O, Purser M, Vekaria RM. The Humanistic and Economic Burden of Chronic Idiopathic Constipation in the USA: A Systematic Literature Review. Clin Exp Gastroenterol 2020;13:255-65. [PMID: 32765039 DOI: 10.2147/CEG.S239205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
251 Camilleri M. American college of gastroenterology monograph on the management of irritable bowel syndrome. Expert Opin Pharmacother 2015;16:629-32. [PMID: 25582735 DOI: 10.1517/14656566.2015.1002770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
252 De Giorgio R, Ruggeri E, Stanghellini V, Eusebi LH, Bazzoli F, Chiarioni G. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol 2015;15:130. [PMID: 26467668 DOI: 10.1186/s12876-015-0366-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
253 El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med 2017;40:607-13. [PMID: 28731144 DOI: 10.3892/ijmm.2017.3072] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 9.2] [Reference Citation Analysis]
254 Wolever TMS, Rahn M, Dioum EH, Jenkins AL, Ezatagha A, Campbell JE, Chu Y. Effect of Oat β-Glucan on Affective and Physical Feeling States in Healthy Adults: Evidence for Reduced Headache, Fatigue, Anxiety and Limb/Joint Pains. Nutrients 2021;13:1534. [PMID: 34062937 DOI: 10.3390/nu13051534] [Reference Citation Analysis]
255 Kuchnia AJ, Conlon B, Greenberg N. Natural Bioactive Food Components for Improving Enteral Tube Feeding Tolerance in Adult Patient Populations. Nutr Clin Pract 2017. [DOI: 10.1177/0884533617722164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
256 Bellini M, Tonarelli S, Barracca F, Rettura F, Pancetti A, Ceccarelli L, Ricchiuti A, Costa F, de Bortoli N, Marchi S, Rossi A. Chronic Constipation: Is a Nutritional Approach Reasonable? Nutrients 2021;13:3386. [PMID: 34684388 DOI: 10.3390/nu13103386] [Reference Citation Analysis]
257 Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018;93:1858-1872. [PMID: 30522596 DOI: 10.1016/j.mayocp.2018.04.032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
258 Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S, Fox SM, Bochenek W, Weissman D, Currie MG, Lembo AJ. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Review of Gastroenterology & Hepatology 2019;13:397-406. [DOI: 10.1080/17474124.2019.1575203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
259 Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil 2019;31:e13461. [PMID: 30232834 DOI: 10.1111/nmo.13461] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
260 Pranami D, Sharma R, Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs Ther Perspect 2017;33:228-33. [DOI: 10.1007/s40267-017-0384-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
261 Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA, Ebrahimi Daryani N, Kashani L, Akhondzadeh S. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2020;45:97-104. [PMID: 31486103 DOI: 10.1111/jcpt.13032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
262 Fleming MA 2nd, Ehsan L, Moore SR, Levin DE. The Enteric Nervous System and Its Emerging Role as a Therapeutic Target. Gastroenterol Res Pract 2020;2020:8024171. [PMID: 32963521 DOI: 10.1155/2020/8024171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
263 Kröner PT, Tolaymat OA, Bowman AW, Abril A, Lacy BE. Gastrointestinal Manifestations of Rheumatological Diseases. Am J Gastroenterol 2019;114:1441-54. [PMID: 31205138 DOI: 10.14309/ajg.0000000000000260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
264 Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42:491-503. [PMID: 26076071 DOI: 10.1111/apt.13283] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
265 Bassotti G, Usai Satta P, Bellini M. Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options. Clin Exp Gastroenterol 2021;14:413-28. [PMID: 34712055 DOI: 10.2147/CEG.S256364] [Reference Citation Analysis]
266 Khlevner J, Park Y, Margolis KG. Brain-Gut Axis: Clinical Implications. Gastroenterol Clin North Am 2018;47:727-39. [PMID: 30337029 DOI: 10.1016/j.gtc.2018.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
267 Pustovit RV, Furness JB, Rivera LR. A ghrelin receptor agonist is an effective colokinetic in rats with diet-induced constipation. Neurogastroenterol Motil. 2015;27:610-617. [PMID: 25616061 DOI: 10.1111/nmo.12517] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
268 Luo D, Qu C, Lin G, Zhang Z, Xie J, Chen H, Liang J, Li C, Wang H, Su Z. Character and laxative activity of polysaccharides isolated from Dendrobium officinale. Journal of Functional Foods 2017;34:106-17. [DOI: 10.1016/j.jff.2017.04.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
269 Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28:26-35. [PMID: 26690872 DOI: 10.1111/nmo.12716] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
270 Zhuang Z, Chen M, Niu J, Qu N, Ji B, Duan X, Liu Z, Liu X, Wang Y, Zhao B. The Manufacturing Process of Kiwifruit Fruit Powder with High Dietary Fiber and Its Laxative Effect. Molecules 2019;24:E3813. [PMID: 31652679 DOI: 10.3390/molecules24213813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
271 Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, Fichna J. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag 2016;12:771-5. [PMID: 27257381 DOI: 10.2147/TCRM.S83722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
272 Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med 2017;129:872-88. [PMID: 28936910 DOI: 10.1080/00325481.2017.1383819] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
273 Buggio L, Somigliana E, Borghi A, Vercellini P. Probiotics and vaginal microecology: fact or fancy? BMC Womens Health 2019;19:25. [PMID: 30704451 DOI: 10.1186/s12905-019-0723-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
274 Chung HG, Min YW, Lee C, Hong SN, Won JY, Jang JA, Kim CH, Chang DK. Effects of Novel Probiotics in a Murine Model of Irritable Bowel Syndrome. Korean J Gastroenterol 2020;75:141-6. [PMID: 32209802 DOI: 10.4166/kjg.2020.75.3.141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
275 Vakil N, Stelwagon M, Shea EP, Miller S. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J 2016;4:413-22. [PMID: 27403308 DOI: 10.1177/2050640615600114] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
276 Talley NJ, Holtmann G, Walker MM. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol. 2015;50:601-613. [PMID: 25917563 DOI: 10.1007/s00535-015-1076-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
277 Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43 Suppl 1:37-49. [PMID: 26618924 DOI: 10.1111/apt.13437] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
278 Quigley EM, Fried M, Gwee KA, Khalif I, Hungin AP, Lindberg G, Abbas Z, Fernandez LB, Bhatia SJ, Schmulson M, Olano C, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50:704-713. [PMID: 27623513 DOI: 10.1097/mcg.0000000000000653] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
279 Shah ED, Staller K, Nee J, Ahuja NK, Chan WW, Lembo A, Brenner DM, Siegel CA, Chey WD. Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis. Am J Gastroenterol 2021. [PMID: 34388141 DOI: 10.14309/ajg.0000000000001403] [Reference Citation Analysis]
280 Lacy BE, Ford AC, Talley NJ. Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards? Am J Gastroenterol 2018;113:167-9. [PMID: 29206817 DOI: 10.1038/ajg.2017.442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
281 Ali H, Pamarthy R, Sarfraz S. Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review. Cureus 2021;13:e14306. [PMID: 33968518 DOI: 10.7759/cureus.14306] [Reference Citation Analysis]
282 Grundmann O, Yoon SL, Mason S, Smith K. Gastrointestinal symptom improvement from fiber, STW 5, peppermint oil, and probiotics use-Results from an online survey. Complement Ther Med 2018;41:225-30. [PMID: 30477844 DOI: 10.1016/j.ctim.2018.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
283 Simrén M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018;15:589-605. [PMID: 29930260 DOI: 10.1038/s41575-018-0034-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 17.0] [Reference Citation Analysis]
284 Ballou S, Kaptchuk TJ, Hirsch W, Nee J, Iturrino J, Hall KT, Kelley JM, Cheng V, Kirsch I, Jacobson E, Conboy L, Lembo A, Davis RB. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. Trials 2017;18:234. [PMID: 28545508 DOI: 10.1186/s13063-017-1964-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
285 Pannemans J, Corsetti M. Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders? Curr Opin Pharmacol 2018;43:53-8. [PMID: 30189347 DOI: 10.1016/j.coph.2018.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
286 Wang QS, Wang YL, Zhang WY, Li KD, Luo XF, Cui YL. Puerarin from Pueraria lobata alleviates the symptoms of irritable bowel syndrome-diarrhea. Food Funct 2021;12:2211-24. [PMID: 33595580 DOI: 10.1039/d0fo02848g] [Reference Citation Analysis]
287 Duncan PI, Enters-Weijnen CF, Emami N, McLean P, Nunes T, Beaumont M, Crabbe R, Whelan K, Scott SM, deWit NJ, Weits T, Bergonzelli G, Grobbee DE. Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial. Nutrients 2018;10:E920. [PMID: 30029461 DOI: 10.3390/nu10070920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
288 Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol 2017;10:253-75. [PMID: 28203283 DOI: 10.1177/1756283X16663396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
289 Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66:966-974. [PMID: 28232472 DOI: 10.1136/gutjnl-2016-313425] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 12.6] [Reference Citation Analysis]
290 Mcrorie JW. The Physics of Fiber in the Gastrointestinal Tract. Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019. pp. 19-32. [DOI: 10.1016/b978-0-12-814468-8.00002-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Chey WD, Whelan K. Dietary guidelines for irritable bowel syndrome are important for gastroenterologists, dietitians and people with irritable bowel syndrome. J Hum Nutr Diet 2016;29:547-8. [PMID: 27599641 DOI: 10.1111/jhn.12413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
292 Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2016;151:1113-21. [PMID: 27528177 DOI: 10.1053/j.gastro.2016.08.003] [Cited by in Crossref: 129] [Cited by in F6Publishing: 112] [Article Influence: 21.5] [Reference Citation Analysis]
293 Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. Am J Gastroenterol 2019;114:1502-11. [PMID: 31356229 DOI: 10.14309/ajg.0000000000000327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
294 Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, Mullin GE. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med 2019;19:21. [PMID: 30654773 DOI: 10.1186/s12906-018-2409-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 13.7] [Reference Citation Analysis]
295 Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf. 2016;15:983-991. [PMID: 27149541 DOI: 10.1080/14740338.2016.1186639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
296 Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci 2017;62:2455-63. [PMID: 28589238 DOI: 10.1007/s10620-017-4598-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
297 Garnock-Jones KP. Prucalopride: A Review in Chronic Idiopathic Constipation. Drugs 2016;76:99-110. [PMID: 26628294 DOI: 10.1007/s40265-015-0518-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
298 El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2015; 21(25): 7621-7636 [PMID: 26167065 DOI: 10.3748/wjg.v21.i25.7621] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
299 Rezaie A, Park SC, Morales W, Marsh E, Lembo A, Kim JH, Weitsman S, Chua KS, Barlow GM, Pimentel M. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci 2017;62:1480-5. [PMID: 28451914 DOI: 10.1007/s10620-017-4585-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
300 Cudmore S, Doolan A, Lacey S, Shanahan F. A randomised, double-blind, placebo-controlled clinical study: the effects of a synbiotic, Lepicol, in adults with chronic, functional constipation. Int J Food Sci Nutr 2017;68:366-77. [PMID: 27776217 DOI: 10.1080/09637486.2016.1244661] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
301 Chey WD. Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology 2016;111:366-71. [DOI: 10.1038/ajg.2016.12] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
302 Baffy N, Foxx-Orenstein AE, Harris LA, Sterler S. Intractable Constipation in the Elderly. Curr Treat Options Gastroenterol 2017;15:363-81. [PMID: 28801825 DOI: 10.1007/s11938-017-0142-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
303 Kamiński M, Skonieczna-Żydecka K, Łoniewski I, Koulaouzidis A, Marlicz W. Are probiotics useful in the treatment of chronic idiopathic constipation in adults? A review of existing systematic reviews, meta-analyses, and recommendations. Prz Gastroenterol 2020;15:103-18. [PMID: 32550942 DOI: 10.5114/pg.2019.86747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Li F, Fu T, Tong WD, Liu BH, Li CX, Gao Y, Wu JS, Wang XF, Zhang AP. Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2016;91:456-468. [PMID: 27046523 DOI: 10.1016/j.mayocp.2016.01.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
305 Lee TY, Hsieh TC, Sung HC, Chen WL. Internet-Delivered Cognitive Behavior Therapy for Young Taiwanese Female Nursing Students with Irritable Bowel Syndrome-A Cluster Randomized Controlled Trial. Int J Environ Res Public Health 2019;16:E708. [PMID: 30818837 DOI: 10.3390/ijerph16050708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Haber SL, El-Ibiary SY. Peppermint oil for treatment of irritable bowel syndrome. Am J Health Syst Pharm 2016;73:22, 24, 26 passim. [PMID: 26721531 DOI: 10.2146/ajhp140801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
307 Rej A, Aziz I, Tornblom H, Sanders DS, Simrén M. The role of diet in irritable bowel syndrome: implications for dietary advice. J Intern Med 2019;286:490-502. [DOI: 10.1111/joim.12966] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
308 Sajadi M, Davodabady F, Naseri-salahshour V, Harorani M, Ebrahimi-monfared M. The effect of foot reflexology on constipation and quality of life in patients with multiple sclerosis. A randomized controlled trial. Complementary Therapies in Medicine 2020;48:102270. [DOI: 10.1016/j.ctim.2019.102270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
309 Levio S, Cash BD. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol 2017;10:715-25. [PMID: 28932272 DOI: 10.1177/1756283X17721152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
310 Wang YP, Herndon CC, Lu CL. Non-pharmacological Approach in the Management of Functional Dyspepsia. J Neurogastroenterol Motil 2020;26:6-15. [PMID: 31751504 DOI: 10.5056/jnm19005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]